1 |
Harper DM, Franco EL, Wheeler C, et al (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 364, 1757-65.
DOI
|
2 |
Harper DM, Franco EL, Wheeler C, et al (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet, 367, 1247-55.
DOI
|
3 |
Hildesheim A, Schiffman MH, Gravitt PE, et al (1994). Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis, 169, 235-40.
DOI
|
4 |
International Agency for Research on Cancer (2005). IARC Handbooks of Cancer Prevention. Cervix Cancer Screening. Lyon: IARC Press.
|
5 |
Jo H, Kim JW (1998). Implications of HPV infection in uterine cervical cancer. Sex Transm Inf, 74, 101-9.
DOI
|
6 |
Li TT, Zhao LN, Liu ZG, Han Y, Fan DM (2005). Regulation of apoptosis by the papillomavirus E6 oncogene. World J Gastroenterol, 11, 931-7.
DOI
|
7 |
Longworth MS, Laimins LA (2004). Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol Biol Rev, 68, 362-72.
DOI
ScienceOn
|
8 |
Mayrand MH, Duarte-Franco E, Rodrigues I, et al (2007). Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med, 357, 1579-88.
DOI
ScienceOn
|
9 |
Miller AB (1992). Cervical cancer screening programmes: managerial guidelines. Geneva: World Health Organization.
|
10 |
Motoyama S, Ladines-Llave CA, Luis Villanueva S, Maruo T (2004). The role of human papillomavirus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci, 50, 9-19.
|
11 |
Bharadwaj M, Hussain S, Nasare V, Das BC (2009). HPV & HPV vaccination: Issues in developing countries. Indian J Med Res, 130, 327-33.
|
12 |
Ronco G, Segnan N, Giorgi-Rossi P, et al (2006). Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst, 98, 765-74.
DOI
|
13 |
Sankaranarayanan R, Okkuru Esmy P, Rajkumar R, et al (2007). Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet, 370, 398-406.
DOI
|
14 |
Solomon D, Schiffman M, Tarone R (2001). Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst, 93, 293-99.
DOI
ScienceOn
|
15 |
Stamenkovic I (2000). Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol, 10, 415-33.
DOI
ScienceOn
|
16 |
Stoler MH (2001). HPV for cervical cancer screening: is the era of the molecular pap smear upon us? J Histochem Cytochem, 49, 1197-8.
DOI
|
17 |
Villa LL, Costa RL, Pettac A, et al (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6, 271-8.
DOI
ScienceOn
|
18 |
Villa LL, Ault KA, Guiliano AR, et al (2006). Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 24, 5571-83.
DOI
|
19 |
Villa LL, Costa RLR, Petta CA, et al (2007). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus like particle vaccine through 5 years follow-up. Br J Cancer, 6, 1459-66.
|
20 |
Villers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H (2004). Classification of papillomaviruses. Virology, 324, 17-27.
DOI
ScienceOn
|
21 |
Vizcaino AP, Moreno V, Bosch FX, et al (2000). International trends in incidence of cervical cancer: II. Squamous - cell carcinoma. Int J Cancer, 86, 429-35.
DOI
ScienceOn
|
22 |
Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.
DOI
ScienceOn
|
23 |
Zur Hausen H (1991). Viruses in human cancers. Science, 254, 1167-73.
DOI
|
24 |
Zur Hausen H (2002). Papillomaviruses and cervical cancer. Nat Rev, 2, 342-50.
DOI
ScienceOn
|
25 |
Bovicelli A, Bristow RE, Montz FJ (2000). HPV testing: where are we now? Anticancer Res, 20, 4673-80.
|
26 |
Bosch FX, Lorincz A, Munoz N, et al (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 55, 244-65.
DOI
|
27 |
Bosch F (2003). Epidemiology of human papillomavirus infections: new options for cervical cancer prevention. Salud Publica Mex, 45, 326-39.
|
28 |
Bosch FX, Castellsague X, S de Sanjose (2008). HPV and cervical cancer: screening or vaccination? Br J Cancer, 98, 15-21.
DOI
|
29 |
Cuzick J, Clavel C, Petry KU, et al (2006). Overview of the european and north American studies on HPV testing in primary cervical cancer screening. Int J Cancer, 119, 1095-101.
DOI
|
30 |
Dabash R, Vajpayee J, Jacob M, et al (2005). A strategic assessment of cervical cancer prevention and treatment services in 3 districts of Uttar Pradesh, India. Reprod Health, 2, 11.
|
31 |
Das BC, Hussain S, Nasare V, Bharadwaj M (2008). Prospects and prejudices of human papillomavirus vaccines in India. Vaccine, 26, 2669-79.
DOI
|
32 |
Denny L, Quinn M, Sankaranarayanan R (2006). Chapter 8: Screening for cervical cancer in developing countries. Vaccine, 24, 71-7.
DOI
ScienceOn
|
33 |
Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002 (2004). Cancer incidence, mortality and prevalence worldwide, version 2.0. IARC Cancer Base No. 5 Lyon, France: IARC Press.
|
34 |
Ganguly N, Parihar SP (2009). Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci, 34, 113-23.
DOI
|